Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Ishtiaq Ali Saaem is sentenced to three years of probation following a guilty plea to charges he obstructed a federal investigation into his efforts to acquire the deadly toxin ricin.
The FDA requested additional data analyses from the pediatric studies that Merck stated it has submitted. The final decision is expected on July 1, 2022.
The increased resignation of employees is making it difficult for companies to keep up with production and meet deadlines. Here are the best ways to attract and keep top talent in the pharma industry.
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
Although the data suggests the vaccines are extremely effective and generally safe, analysis is still coming in about adverse events as well as effectiveness in specific patient populations.
The Telomere-to-Telomere (T2T) Consortium has completed the sequencing of the entire genome, referring to it as T2T-CHM13.
Silverback is halting its clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave it with more cash reserves.
Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.
Origami’s precision technology platform, Oricision™, is focused on diseases that affect the central nervous system rather than oncology.
Vertex Pharmaceuticals has announced meaningful results from two Phase II studies of its therapeutic VX-548. It is a non opioid pain medication that promises results.
When Sekar Kathiresan’s brother unexpectedly died from a heart attack, he changed the course of his life to found a company with a novel medicine that may prevent them.
Ginkgo Bioworks reported its 2021 financials today, and the $1.7 billion of stock-based compensation caught everyone’s attention.